Company name: Magneto Thrombectomy Solutions
Website: https://www.magts.com/
CEO name: Benny Dilmoney

CATEGORY: **Medical Devices**

SESSIONS
Do we Know Enough About the Brain to Treat Neurological Disorders?
Are Medical Devices Still Relevant in the Context of New Biology?

- **Executive Summary / Investment Rational**
  Magneto is developing thrombectomy solutions for treating patients with vascular occlusions, including Pulmonary Embolism (PE), stroke and Deep Vein Thrombosis (DVT). PE is the third most common cause of cardiovascular death. Stroke is the leading cause of disability worldwide and the second leading cause of death. The incidence of DVT in the whole general population is around 5 per 10,000 per annum.
- **Core Technology**
  Magneto has developed novel catheter-based thrombectomy systems that is based on the electric properties of blood clots. The Magneto's catheters are charged positively and generate attraction with the inherently negatively charged clots. Unique properties include reaching distal clots, minimal interaction with the vessel wall, the ability to withdraw all clots' types, withdrawal of clots in all sizes, and less fragmentations.
- **Product Profile/Pipeline**
  Magneto has developed several catheter-based systems, each specifically designed to treat the medical conditions mentioned above. Our portfolio includes the eTrieve™ PE Kit for PE, the eTrieve™ Microcatheter for stroke and the eBasket™ System for DVT.
- **Business Strategy**
  Magneto is focusing on the PE market, which has grown significantly and is characterized by a high reimbursement, little number of players, existence of dedicated PERT teams and fast referral to interventional treatment. Magneto is launching a US pivotal trial, which is the leading market today. Other markets will follow the US one. Work on the other indications is progressing.
- **What's Next?**
  Magneto advances in all therapeutic fields. In PE, we are launching a US pivotal trial. For stroke we are continuing an OUS FIH study and DVT is in R&D phase, facing pre-clinical and initial clinical studies in 2025 The company is raising funds for supporting US approval of the PE product, and continued work on the other indications.